Target Price | $169.83 |
Price | $146.67 |
Potential |
15.79%
register free of charge
|
Number of Estimates | 28 |
28 Analysts have issued a price target Neurocrine Biosciences, Inc. 2026 .
The average Neurocrine Biosciences, Inc. target price is $169.83.
This is
15.79%
register free of charge
$210.00
43.18%
register free of charge
$125.24
14.61%
register free of charge
|
|
A rating was issued by 34 analysts: 29 Analysts recommend Neurocrine Biosciences, Inc. to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2026 of
15.79%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.36 | 2.84 |
24.81% | 20.75% | |
EBITDA Margin | 25.90% | 22.97% |
17.48% | 11.32% | |
Net Margin | 14.49% | 15.78% |
9.51% | 8.90% |
30 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2025. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 3.29 | 4.53 |
33.20% | 37.69% | |
P/E | 32.36 | |
EV/Sales | 4.77 |
29 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Needham |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Locked
Needham:
Locked
➜
Locked
|
Sep 22 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 05 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 05 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 31 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Jul 31 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.